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In this Ph.D. project we have explored the possibiïties of using alkaline
phosphatase to treat LPS-induced sepsis, by detoxifying this initiator of the disease.
Sepsis is still a major problem woddwide, for which currendy no effective
treatment has been described that is applicable for most of the patients. LPS is a
molecule from the outer membrane of Gram-negative bacteria, and it induces the
production of many different inflammatory mediators after entering the body. The
production of these mediators may in principle be beneficial to deal with this 'non-
self antigen in the human body, but an excess of multiple mediators in the
systemic circulation may in fact abrogate this process. The pathophysiology of
LPS-induced sepsis is described in chapter 1 as well as various therapeutic agents
for sepsis that have been developed in recent years. They are mainly aimed at
counteracting one of the LPS-induced pro-infl^mm^tory mediators involved in the
disease process. We chose a different approach of detoxification of LPS in uiuo
using the enzyme alkaline phosphatase (AP). \Xle showed that AP is able to
dephosphorylate the lipid A moiety of LPS, and administration of AP to mice is
associated with less bioactivity of LPS.
Chapter 2 describes the in uitro and the in uiuo effects of LPS and monophosphoryl
lipid A (MPIÁ), the dephosphorylated form of the LPS. These studies were
conducted in order to explore the potential toícity of this dephosphorylated LPS-
form. MPLA appearcd completely non-toxic in our models. Furthermore, we
showed the LPS-dephosphorylating abilities of endogenous alkaline phosphatase
(AP) in different tissues in the mouse and established that MPIÁ is no longer a
substrate for this enzyme. To examine the therapeutic activity of exogenous AP in
LPS-induced sepsis, we used the placental isoform of AP (plAP) for a survival
study. This study showed a cleaily increased survival rate of pLAP- treated mice as
compared to mice that received only LPS.
To examine the effects of p[AP in uiuo, we performed further studies that are
described in chapter 3. We used the placental as well as the intestinal isoform of
AP, and characterised both isoforms. PLAP and ciAP were obtained as highly pure
preparations. \X/e showed that after pLAP administration, plAP could be detected
for a daitvely long period of time in plasma (>24 hours), whereas ciAP was
completely removed from the circulation within 2 hours. The mice received pLAP
intravenously, simultaneously with LPS/galactosamine that was iniected
intraperitoneally. At different time points, samples of the blood were taken and
several tissues were harvested for further analysis. S7e showed that administration
of pLAP strongly reduced the LPS-induced TNFcr peak levels as well as the NO
levels as compared to the control mice that received no tÍeatment. The
administration of plAP also had a significant effect on the body-temperature of the
septic mice: in contrast to control animals receiving only LPS, the AP-treated mice
showed quite normal body temperatures. In addition, pLAP also reduced the
amount of ROS-producing cells in the lungs and reduced the expression of the cell
adhesion molecules VCAM and PECAM in the liver. To exclude whether the
observed effect of pLAP could be described solely to this isoform, we also tested
calf intestinal alkaline phosphatase (ciAP). V/e focussed on peak TNFcr, levels 2
hours after the injections, as this cytokine is a well-known eady marker for sepsis.
Using this alternative isoform (ciAP) similar results were obtained as described for
pLAP, despite the ptofound difference in plasma half-life. This indicates that the
protective effects seen with pLAP are not isoform speciÍic.
Since treatment of sepsis in the clinic generally starts after the onset of the disease,
we investigated the effects of pLAP in another model, which resembles the cl,inical
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situation moÍe closely. In this study, which is described in chapter 4, the mice were
injected intraperitoneally with whole Escheichia coli bacteria while pLAP was
administered after the detection of bacteria in the blood circulation. The overall
findings of this study were quite similar to the studies performed using the LPS-
challenge model. PLAP appeared to have a protecrive effect in reducing the NO
levels 24 hours after the pLAP injections, plAP also improved the body
temperatures of the mice at t=7 hours. Furthermore, a major effect was observed
on survival in this mouse model. Treatment of the mice with pLAP increased the
survival up to 100%, wheteas the survival rate in the non-treated group was * 60
o/o. To study the dephosphorylating capacities of plAP with LPS as a substrate, we
performed a phosphate release assay and showed that pLAP was able to
enzymaically release approximately 33 o/o of the LPS-bound phosphate. These
results cleady showed the in yitro activity of AP. Unfortunately, currently the LPS-
dephosphorylating efficacy of AP in uiuo can not be direcdy measured. This
represents a maior challenge for this line of research in the future.
In the chapters 5 and 6 we describe the studies performed with modified pJAP-
preparations. As described in the introduction, the main cells involved in sepsis are
the mactophages and endothelial cells that produce an excess amount of
inflammatory mediators. We consideted the possibility to achieve an enhanced
distribution of AP to these two cell tlpes, as at these sites LPS will rapidly
accumulate in uiao. In these studies we showed drat alkaline phosphatase, with a
complex folding stftrcture and many glycosylation sites, can be chemically modified
with regard to the overall charge. \)7e obtained a polyanionic succinylated enzyme
(succ-p[AP) that still retained at least some enzymatic acrivity, although the net
phosphatase activity after succinylation appeared to be significantly atteil)ateá. In
uitro studtes revealed an increased binding of succ-plAP to endothelial cells in the
pïesence of LPS. In accotdance with these in aitro observations, in uiuo sudtes
showed a reduced half-life of succ-pLAP in plasma as compared to non-modified
pLAP. However, no beneÍicial effect was obtained using succ-plAP over non-
modified pLAP in the LPS/galactosamine mouse model. In contrast to the study
described in chapter 3, where administration of native pLAP exerted a protective
effect in mice challenged with LPS and reduced plasma levels of TNFcr
profoundly, administration of succ-pLAP in this mouse model even enhanced the
TNFcr response strongly. Síe inferred from these observations that either succ-
p[AP binds LPS and presents it to the CD14/ toll like receptoÍ or that LPS binds
to succ-plAP and is internalized by the scavengeÍ receptor, thereby causing
activation of the target cells.
In chapter 6 we describe that pLAP can also be mannosylated. This mannosylated
pLAP (mann-plAP) was found to bind to macrophages in uitro and showed a
reduced half-life in uiuo as compared to non-modified pLAP. However, similar to
succ-plAP, mann-pLAP potentiated the TNFcr- Ievel in wuo signiftcandy. No
enhanced TNFcr expression was observed when the mice received the modified
preparations succ- or mann-plAP without LPS, indicating that this is not a direct
effect of the modified enzymes. Using another modified form of p[AP, fucose-
pLAP, to deliver the LPS-dephosphorylating enzyme mainly to macrophages, the
potentiation of the LPS-response by the charge- and sugar-modified AP could be
confirmed.
Conclusions
Taken togetheÍ, these studies describe a potential tole of AP in Íighting sepsis ot
systemic inflammatory Íesponses initiated by LPS. PLAP was shown to
dephosphorylate the substrate LPS in uitro using a phosphate-release assay as well as
by employing histochemical techniques.
PIAP cleady enhanced the survival of E. coli bacteria-injected mice and LPS-
challenged mice. The enhanced survival was accompanied with lower plasma levels
of various markers for sepsis. In the experiments described in this thesis, nitric
oxide Q.JO) was chosen as a late marker and TNFa as an eady marker of sepsis.
Other markers included tissue infiltration of reactive oxygefl species (ROS), a
decrease in the body-temperature and the expression of cell adhesion molecules
such as VCAM and PECAM. Based on these parameteÍs a major pÍotective effect
was found for the non-modiÍied AP.
PLAP appeared suitable for chemical modification, as observed after succinylation,
mannosylation and fucosylation of the enzyme. These chemicai modifications
profoundly affected the plasma disappearance rate of the enzyme. However, none
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of these modifications did enhance the therapeutic efficacy of the enzyme: on the
contrary, they rather worsened the condition when administered to the mice in the
acute LPS-induced sepsis model.
Based on the efficacy studies in uiuo, using different isoforms of AP as well as
chemically modified forms of AP, all with a different organ and cellular distribution
pattern, the following conclusions can be drawn.
The unmodified, naturally occurring forms of AP (placental and intestinal AP) are
both quite effective in reducing the LPS response, despite their profound
difference in plasma half life and organ distribution. Placental AP remains in the
plasma for many hours due to the terminal sialic acid groups, which prevent uptake
by various sugar Íecognizing receptors. In contÍast, intestinal AP is rapidly cleared
from the liood (t'/z = 8 min) by hepatocytes, via the asialoglycoprotein receptor
that recogtizes the terminal galactose moieties as present in this form of AP 1;2,
Modified forms of AP, targeted at either I(upffer cells (I(C) or liver endothelial
cells, strongly potentiated the response upon LPS, but did not elicit a response
without LPS. Our studies indicate that these modified forms are able to bind LPS.
This phenomerion may explain the above mentioned potentiating effect because
the increased targeting of AP to sinusoidal endothelial cells (SEC) and KC at the
same time may lead to an increased exposure of LPS to these cell types. This
obviously will lead to a further activation of these effector cells of sepsis.
It can be concluded that the preferred site of action of AP is blood plasma
(placental AP) or the surface of the hepatocytes (intestinal AP). After LPS
administration, endogenous AP activity rapidly declines in plasma (chapter 2) and
subsequendy increases above baseline values 3. Simultaneously, after LPS
administration, endogenous AP expression in the livet is highly upregulated on the
plasma membrane of hepatocytes a. The accumulation of effective preparations of
AP at these very same sites may therefore mimic the normal physiological
response. Exogenous AP may therefore serve to support the endogenous response
to LPS in patients suffering either from an increased LPS influx from the gut or
exhibit a deficient endogenous AP response.
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Further perspectives
To date, treatment of sepsis is still a major problem in intensive care units s. A
successful pharmacological intervention is hampered by the heterogeneity of
patients that develop sepsis. In many cases, sepsis is a secondary condition to
different under\ing diseases 6. Also differences between the animal models of
sepsis that do not cleady reflect the complicated situation seen in humans, make it
difficult to simply extrapolate results from the thetapies tested in laboratory
animals to the clinical situation a;r. À[ of these factors have led to a situation where
there is no efÍicient therapy available for this disease.
In this thesis we have described a role fot alkal-ine phosphatase (AP) in providing
protection from LPS-induced sepsis. N7e used two different mouse-models, using
the same Balb/c mouse-strain. In the first model, AP treatment was initiated
simultaneous with the LPS-challenge, whereas in the second model AP was
administered after sepsis had been induced by E. coli bacteria. The latter situation
more closely mimics the clinical condition.
The series of experiments described in this thesis sttongly suppoït a role for AP in
detoxifying LPS by dephosphorylation. The significance of this eflzyrr'e in aiuo as an
intrinsic part of the first line of host defence against bacterial infections remains to
be elucidated. Our studies did not address this issue. N7e tather studied the effects
of exogenous AP. However, our studies may shed some light upon the biological
function of this enzyme, a function that remained quite obscure despite its
presence in neady all tissues of the body. The specific locabzaion of this enzyme in
the body fits with the proposed role as a protective enzyme. AP is located as an
GPl-anchored enzyme at the outside of plasma membranes of epithelial cells in the
intestinal lumen, along endothelial cells in all organs, including the adrenals. It is
also present within macrophages and in the CD14-positive granula of neutrophils.
At all these particular sites LPS accumulates in uiuo 8;e. Moreover, a clearly
enhanced expression of the enzyme is found in plasma and in the liver after LPS
administration.
LPS detoxification may not be the only function of the enzyme since for example
its localization in bone-tissue seems not relevant for an LPS-detoxifying enzyme.
Yet a specific roie of AP in bone formation has already been demonstrated 10.
144
As demonstrated here, exogenous AP exerts protective effects in aiuo in rwo
different experimental models of sepsis in mice. In aitro we demonstrated that AP
might direcdy att^ck LPS itself. This can be seen as an advantage since AP thereby
affects the causative agent of sepsis rather than secondary mediators. Yet, this may
also be a disadvantage, because LPS has a very short half-life in plasma and is
opsonized rapidly by several proteins, lipids and membrane ÍeceptoÍs. This
causative agent of sepsis therefore is probably gone from plasma when the patients
are hospitalised. AP may therefore be especially effective at the onset of sepsis or it
should be used as a prophylactic therapy when the anticipated risk of sepsis is high.
Patients with high risks for sepsis include: patients with a severe tra;lrm^ induced by
burns, patients with liver diseases or patients undergoing extensive surgical
procedures, like organ transplantations. HoweveÍ, even when the causative agent is
gone from plasma during sepsis, an LPS-detoxifying agent may still be very useful.
Sepsis is often associated with malperfusion of the intestinal vrall and restoration of
the blood circulation may subsequendy lead to reperfusion ischemia with secondary
damage to the vascular wall. This r-:'ay again lead to leakage of LPS or even
bactenal translocation from the intestinal lumen into the blood circula(ton, again
leading to secondary sepsis. In addition, systemic inflammatory response syndrome
(SIRS) is associated with high levels of circulating cpokines and some of them
(INFcr, IL-2, PAF and NO) 11-14 induce an enhanced vascular permeabiïty, which
again may lead to LPS leakage or bacterial translocation from the intestinal lumen.
Many recent Íeports indicate that the latter process plays an important role during
the progression of liver diseases associated with high levels of circulating TNFa 1s.
Via this mechanism AP may also be beneficial for patients with sepsis induced by
Gram-positivebacteria, fungi or other pathogens, in spite of the fact that AP does
not detoxify the initial causative agent during these forms of diseases.
Before AP can be tested in the clinic it should be tested in different large animals
that allow clinical monitoring. AP should be tested in animals that resemble
humans more closely in endotoxin susceptibility and pathophysiology. The pig
makes an excellent model for endotoxin research as it is relatively endotoxine
sensitive and has a cardiovascular physiology th^t is remarkably similar to humans.
As a primate model, the chimpanzee is the perfect model for sepsis-research as its
endotoxine-sensitivity and immunology closely resemble that of humans. However,
the limitations of the readily usage of such animals are obvious.
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The route towards an effective drug against Gram-negative sepsis may still be very
long and many problems will be encountered. This is particulady true for
proteinaceous agents such as AP. AP may be used as patt of such a therapy.
Alternatively it could be used together with drugs that inhibit the effects of the
most prominent cytokines. It is not expected that a complicated and a rapidly
progressing disease like sepsis can be cured by one drug. Howevet, a drug that
directly affects the causative agent of sepsis could well be incorporated in a
therapeutic combination. The fact that LPS is rapidly cleared from the circulation
calls for a search for drugs with a similar distribution pattern as LPS. Detailed
investigations on the in uiuo dtstirl>ution of LPS together with an evaluaion of the
pharmacokinetic profile of anti-LPS agents are therefore crucial. The present
studies touched upon that aspect. Although the modified forms of AP were not
curative, they indirecdy ptovided some information about the "ideal" body
localisation of effective LPS-detoxifying agents: the bloodstream oÍ on the surface
of the hepatic parenchymal cells.
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